论文部分内容阅读
骨髓增生异常综合征(myelodysplastic syndrome,MDS)是一类起源于造血干细胞(hematopoietic stem cells,HSC)异常的克隆性疾病,其以无效造血导致外周血细胞减少、一系或多系髓系细胞发育异常及高风险向急性髓系白血病(acute myeloid leukemia,AML)转化为特点,是一种异质性、克隆性的HSC疾病。时至今日,MDS患者在治疗后仍有很高复发率,多数患者仍不可治愈。既往研究发现,MDS肿瘤细胞的异常增殖及患者预后不
Myelodysplastic syndrome (MDS) is a group of clonal diseases which originate from the abnormality of hematopoietic stem cells (HSC), which lead to the decrease of peripheral blood cells and the abnormal development of one or more myeloid cells And high risk of acute myeloid leukemia (AML) is characterized by a heterogeneous, clonal HSC disease. To date, MDS patients still have a high recurrence rate after treatment, and most patients remain incurable. Previous studies have found that abnormal proliferation of MDS tumor cells and prognosis of patients is not